Publication | Closed Access

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

Urological ResearchUrologyVoiding Dysfunctionβ3-Adrenoceptor AgonistMedicineUrogynecologyPharmacotherapyPharmacologyOveractive Bladder